Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis
ConclusionsS-1-based chemotherapy and XELOX are likely to be the most effective adjuvant treatments for patients with resected gastric cancer. 5-FU alone provided little survival benefits as compared with surgery alone. Further clinical trials may be required to investigate S-1-based and XELOX-based adjuvant treatment strategies.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Gastric (Stomach) Cancer | Gastroenterology | Men | Statistics